Piper Sandler Initiates Coverage On Minimed Group with Neutral Rating, Announces Price Target of $16

Benzinga Newsdesk www.benzinga.com Neutral 85.7%

Neg 0% Neu 85.7% Pos 0%

Piper Sandler analyst Matt O'Brien initiates coverage on Minimed Group (NASDAQ:MMED) with a Neutral rating and announces Price Target of $16.